Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Operating Expenses (2016 - 2025)

Guided Therapeutics' Operating Expenses history spans 16 years, with the latest figure at $1.2 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 119.55% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.9 million, a 39.46% increase, with the full-year FY2025 number at $2.9 million, up 39.48% from a year prior.
  • Operating Expenses hit $1.2 million in Q4 2025 for Guided Therapeutics, up from $520000.0 in the prior quarter.
  • Over the last five years, Operating Expenses for GTHP hit a ceiling of $1.5 million in Q2 2023 and a floor of $363000.0 in Q1 2024.
  • Historically, Operating Expenses has averaged $706850.0 across 5 years, with a median of $591000.0 in 2021.
  • Biggest five-year swings in Operating Expenses: skyrocketed 240.08% in 2021 and later crashed 57.59% in 2024.
  • Tracing GTHP's Operating Expenses over 5 years: stood at $476000.0 in 2021, then soared by 82.56% to $869000.0 in 2022, then plummeted by 42.35% to $501000.0 in 2023, then grew by 6.19% to $532000.0 in 2024, then surged by 119.55% to $1.2 million in 2025.
  • Business Quant data shows Operating Expenses for GTHP at $1.2 million in Q4 2025, $520000.0 in Q3 2025, and $842000.0 in Q2 2025.